Sino Biological's Albumin-Bound Paclitaxel Receives ANMAT Approval for Market Launch in Argentina

(Source: Caiwen)

It received marketing approvals in multiple countries, including Peru, Oman, Uruguay, and Georgia, in 2025.

Recently,Kexing BiopharmHaichang Biotech's合作的抗肿瘤药物注射用紫杉醇（白蛋白结合型）获得阿根廷国家药品、食品和医疗器械管理局（ANMAT）下发的注册批件，以此进入阿根廷医药市场。

It is reported that the product "Injectable Paclitaxel (Albumin-Bound)" introduced by Kexing Biopharm was approved for marketing in the EU in 2024, and subsequently received marketing approvals in Peru, Oman, Uruguay, Georgia, and other countries in 2025.